SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-004506
Filing Date
2022-03-01
Accepted
2022-03-01 16:11:24
Documents
14
Period of Report
2022-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ngm-20220301.htm   iXBRL 8-K 38183
2 EX-99.1 ngm-20220301xexx99.htm EX-99.1 91182
6 GRAPHIC ngmlogoprimarycopy.jpg GRAPHIC 26992
  Complete submission text file 0001628280-22-004506.txt   316980

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngm-20220301.xsd EX-101.SCH 1893
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngm-20220301_lab.xml EX-101.LAB 24975
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngm-20220301_pre.xml EX-101.PRE 13174
8 EXTRACTED XBRL INSTANCE DOCUMENT ngm-20220301_htm.xml XML 11292
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 22698095
SIC: 2834 Pharmaceutical Preparations